As of Jun 24
| -0.01 / -0.12%|
The 3 analysts offering 12-month price forecasts for Oramed Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 25.00 and a low estimate of 18.00. The median estimate represents a +145.70% increase from the last price of 8.14.
The current consensus among 3 polled investment analysts is to Buy stock in Oramed Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.